Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma

Hepatology

Volumn 58, Issue 3, 2013, Pages 1042-1053

  Cadamuro, Massimiliano ^a,b   Nardo, Giorgia ^c   Indraccolo, Stefano ^c   Dall'Olmo, Luigi ^a   Sambado, Luisa ^a   Moserle, Lidia ^a,c   Franceschet, Irene ^a   Colledan, Michele ^b   Massani, Marco ^d   Stecca, Tommaso ^d   Bassi, Nicolò ^a,d   Morton, Stuart ^a   Spirli, Carlo ^e   Fiorotto, Romina ^e   Fabris, Luca ^a,b,e,f   Strazzabosco, Mario ^b,e,f  

^a UNIVERSITY OF PADOVA   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d TREVISO REGIONAL HOSPITAL   (Italy)

^e YALE UNIVERSITY   (United States)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ENHANCED GREEN FLUORESCENT PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR D; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; BILE DUCT CARCINOMA; CELL MIGRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROMA; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHOLANGIOCARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION; FIBROBLASTS; HETEROGRAFTS; HUMANS; LYMPHOKINES; MALE; MICE; MICE, SCID; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION;

EID: 84883252924     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26384     Document Type: Article

References (32)

1. Blechacz B, Gores GJ. Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48:308-321.
2. Mueller MM, Fusenig NE. Friends or foes-bipolar effects of the tumor stroma in cancer. Nat Rev Cancer 2004;4:839-849.
3. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006;6:392-401.
4. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:1021-1031.
5. Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011;54:2076-2088.
6. Anderberg C, Pietras K. On the origin of cancer-associated fibroblasts. Cell Cycle 2009;8:1461-1462.
7. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Fidler IJ. Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. Am J Pathol 2006;169:2054-2065.
8. Wang Z, Ahmad A, Li Y, Kong D, Azmi AS, Banerjee S, et al. Emerging roles of PDGF-D signaling pathway in tumor development and progression. Biochim Biophys Acta 2010;1806:122-130.
9. Fabris L, Cadamuro M, Fiorotto R, Roskams T, Spirlì C, Melero S, et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology 2006;43:1001-1012.
10. Spirli C, Okolicsanyi S, Fiorotto R, Fabris L, Cadamuro M, Lecchi S, et al. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology 2010;138:360-371.
11. Fabris L, Cadamuro M, Moserle L, Dziura J, Cong X, Sambado L, et al. Nuclear expression of S100A4 calcium binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 2011; 54:890-899.
12. Indraccolo S, Habeler W, Tisato V, Stievano L, Piovan E, Tosello V, et al. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors. Cancer Res 2002;62:6099-6107.
13. Donnelly DS, Zelterman D, Sharkis S, Krause DS. Functional activity of murine CD34+ and CD34- hematopoietic stem cell populations. Exp Hematol 1999;27:788-796.
14. Abouantoun TJ, Macdonald TJ. Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. Mol Cancer Ther 2009;8:1137-1147.
15. Wang J, Rao Q, Wang M, Wei H, Xing H, Liu H, et al. Overexpression of Rac1 in leukemia patients and its role in leukemia cell migration and growth. Biochem Biophys Res Commun 2009;386:769-774.
16. Florian MC, Dörr K, Niebel A, Daria D, Schrezenmeier H, Rojewski M, et al. Cdc42 activity regulates hematopoietic stem cell aging and rejuvenation. Cell Stem Cell 2012;10:520-530.
17. Lanzardo S, Curcio C, Forni G, Antón IM. A role for WASP Interacting Protein, WIP, in fibroblast adhesion, spreading, and migration. Int J Biochem Cell Biol 2007;39:262-274.
18. Yoshida K, Matsuzaki K, Mori S, Tahashi Y, Yamagata H, Furukawa F, et al. Transforming growth factor-beta and platelet-derived growth factor signal via c-Jun N-terminal kinase-dependent Smad2/3 phosphorylation in rat hepatic stellate cells after acute liver injury. Am J Pathol 2005;166:1029-1039.
19. Boire A, Covic L, Agarwal A, Jacques S, Sherifi S, Kuliopulos A. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 2005;120:303-313.
20. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-890.
21. Kisseleva T, Brenner DA. Is it the end of the line for the EMT? Hepatology 2011;53:1433-1435.
22. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3:512-516.
23. Ustach CV, Taube ME, Hurst NJ, Jr., Bhagat S, Bonfil RD, Cher ML, et al. A potential oncogenic activity of platelet-derived growth factor D in prostate cancer progression. Cancer Res 2004;64:1722-1729.
24. Xu L, Tong R, Cochran DM, Jain RK. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 2005;65:5711-5719.
25. Breitkopf K, Roeyen C, Sawitza I, Wickert L, Floege J, Gressner AM. Expression patterns of PDGF-A, -B, -C, and -D and the PDGF-receptors alpha and beta in activated rat hepatic stellate cells. Cytokine 2005;31:349-357.
26. Okada A, Yaguchi T, Kanno T, Gotoh A, Nakano T, Nishizaki T. PDGF-D/PDGF-ββ receptor-regulated chemotaxis of malignant mesothelioma cells. Cell Physiol Biochem 2012;29:241-250.
27. Miyata M, Rikitake Y, Takahashi M, Nagamatsu Y, Yamauchi Y, Ogita H, et al. Regulation by afadin of cyclical activation and inactivation of Rap1, Rac1, and RhoA small G proteins at leading edges of moving NIH3T3 cells. J Biol Chem 2009;284:24595-24609.
28. Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature 2002;420:629-635.
29. Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: intracellular signalling and the actin cytoskeleton. Cancer Lett 2009;284:122-130.
30. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007;46:1064-1074.
31. Zhu AX, Hezel AF. Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities. Hepatology 2011;53:695-704.
32. Chiorean MV, Guicciardi ME, Yoon JH, Bronk SF, Kaufmanns SH, Gores GJ. Imatinib mesylate induced apoptosis in human cholangiocarcinoma cells. Liver Int 2004;24:687-695.